Results 251 to 260 of about 98,145 (299)

Resistance to anti-HCV protease inhibitors

Current Opinion in Virology, 2011
The era of direct acting antiviral therapy for HCV infection has dawned with the recent approval of the NS3 protease inhibitors telaprevir and boceprevir. The development of DAA therapy is an exciting advance for clinicians and patients, but it will also bring new challenges.
Thompson, A.J., Locarnini, S.A., Beard, M.R.   +2 more
openaire   +3 more sources

Cyclosporine pharmacokinetics in anti‐HCV+ patients

Clinical Transplantation, 2004
Abstract: Background: Cyclosporine (CsA) is a widely used immunosuppressive agent in kidney transplant patients. In Brazil, around 30% of patients awaiting kidney transplantation carry anti‐HCV antibodies. Previous observations suggest altered CsA pharmacokinetics in these patients.Methods: We conducted two pharmacokinetic studies.
Luciano, Wolffenbüttel, Débora D, Poli, Roberto C, Manfro, Luiz Felipe S, Gonçalves   +3 more
openaire   +2 more sources

Sensitivity of an anti‐HCV core peptide ELISA

Journal of Medical Virology, 1992
AbstractA newly developed antibody assay based on a synthetic peptide of 15 amino acids derived from the core region of the hepatitis C virus (HCV) genome was evaluated in serum and plasma panels of (A) 225 haemophiliacs and (B) 44 patients with chronic non‐A, non‐B (NANB) hepatitis, and in (C) sequential serum samples of 9 patients with transfusion ...
Bresters, D., Reesink, H. W., Cuypers, H. T., Jansen, P. L., Mauser-Bunschoten, E. P., van der Poel, C. L., Lelie, P. N.   +6 more
openaire   +2 more sources

False-Positive Anti-HCV in Biliary Cirrhosis

Annals of Internal Medicine, 1991
To the Editors: A high prevalence of anti-hepatitis C virus (HCV) antibodies detected by enzyme immunoassay (HCV-EIA, Ortho) (1) has been reported in patients with various liver diseases, particula...
C, Housset, C, Hirschauer, F, Degos
openaire   +2 more sources

Recent Highlights in the Synthesis of Anti-HCV Ribonucleosides

Current Medicinal Chemistry, 2014
Research on Hepatitis C Virus inhibitors has dramatically increased during the past few years. Actually, several classes of anti-HCV drugs, including NS3/4A protease inhibitors, NS5B polymerase inhibitors, NS4B protein to RNA binding inhibitors, and multifunctional viral protein NS5A inhibitors, are in different stages of development. The RNA dependent
PIPERNO, Anna, CORDARO, Massimiliano, SCALA, ANGELA, IANNAZZO, Daniela   +3 more
openaire   +3 more sources

Rationale for preoperative screening of anti-HCV antibody

Journal of Anesthesia, 1993
We investigated the incidence of the anti-HCV antibody and associated factors in 1,031 surgical patients who had received blood transfusion during or after operation from October 1988 to April 1991, at Kyushu University Hospital. One hundred fifteen patients (11.2%) were anti-HCV positive.
Y, Sakaguchi, S, Inaba, J, Yoshitake
openaire   +2 more sources

The prevalence of anti-HCV antibodies in hemodialysis patients

Gastroenterologia Japonica, 1991
The prevalence of antibodies to hepatitis C virus (anti-HCV) was assessed in 489 hemodialysis patients and 152 members of the staff of dialysis units, using an Ortho HCV Ab ELISA Test. Of the 489 patients, 100 (20.4%) had anti-HCV, a significantly greater rate than was found in either staff members (0.7%, P less than 0.01) or local healthy blood donors
S, Fujiyama, S, Kawano, S, Sato, T, Sato, H, Shimada, K, Matsushita, M, Hara, J, Ito   +7 more
openaire   +2 more sources

Improving anti-HCV therapy.

Discovery medicine, 2007
Hepatitis C virus (HCV) infects about 2% of the world population or approximately 123 million people. The disease causes a significant level of morbidity and mortality among those afflicted. The combination of interferon and ribavirin is effective in many patients.
Stanislas, Pol, Vincent O, Mallet
openaire   +1 more source

Pathological Consequences in Anti-HCV Antibody-Positive Organ Donation to an Anti-HCV Antibody-Negative Recipient

Transplantation Proceedings
The need to expand the pool of available organs for transplantation has meant that the use of marginal organs is increasingly widespread. The advent of antiviral therapy for hepatitis C virus (HCV) has made it possible to consider the donation of organs from HCV-positive donors and even from viremic donors.In HCV-positive to HCV-negative antibody donor
Rossetto A., Adani G. L., Baccarani U., Tulissi P., Bresadola V.   +4 more
openaire   +2 more sources

Prevalence of anti-HCV in two Tanzanian villages

1992
The presence of anti-HCV antibodies was investigated in sera from a total of 123 inhabitants of two Tanzanian villages. In one of the villages, 72.2% of the sera and in the other village, 82.6% of the sera were found to be anti-HCV positive. These values are dramatically higher than other reported prevalences, whereby cross-reactivity between HCV and ...
I, Ilardi, G, Errera, G M, De Sanctis, I G, Barbacini, A, Madera, F, Leone, A, Nderingo, A, Antognoli, L V, Chircu   +8 more
openaire   +2 more sources